semaglutide glp 1 analogue 3mg GLP-1 analogs, new trend in obesity treatment, become even more effective < Pharma < Article Alkem Launches India's First Single-Shot

OASIS 1 tested 50 mg and found greater weight loss, 4 raising the question of whether the currently approved dose represents the optimal balance of efficacy and tolerability

Activation of a cAMP-regulated Ca2+-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1

BNP as a new biomarker of cardiac thyroid hormone function

In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]

Braca is the lead author of a new study recently presented at the European Academy of Neurology (EAN) Congress 2025 that has found that glucagon-like peptide-1 (GLP-1) receptor agonist medications used to treat type 2 diabetes and obesity may help cut a persons monthly migraine days by about half

Here is a summary of results across the major trials